FDA blesses GSK/Theravance COPD drug Anoro Ellipta
This article was originally published in Scrip
GlaxoSmithKline and Theravance on 18 December won US approval of Anoro Ellipta, a combination of umeclidinium bromide 62.5mcg, a long-acting muscarinic antagonist (LAMA), and vilanterol 25mcg, a long-acting beta2 agonist (LABA), for the long-term, once-daily maintenance of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.